Effect of Hyperbaric Oxygen Therapy(HBOT) on Patients With Sudden Sensorineural Hearing Loss(SSNHL) and Coagulation Function

Effect of Hyperbaric Oxygen Therapy on Patients With Sudden Sensorineural Hearing Loss and Coagulation Function

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06819202

Enrollment

1309

Registered

2025-02-11

Start date

2025-06-01

Completion date

2025-12-01

Last updated

2025-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sudden Sensorineural Hearing Loss (SSNHL), Hyperbaric Oxygen Therapy

Brief summary

The objective of this observational study was to understand the effect of HBO on patients with SSNHL and its association with coagulation function and prognosis. The main question it aims to answer is whether HBO therapy can improve outcomes and coagulation function in patients with SSNHL. The prognosis of SSNHL patients receiving HBO and SSNHL patients not receiving HBO were compared

Interventions

OTHERHyperbaric oxygen treatment

HBO therapy is the process of inhaling 100% pure oxygen in an environment above one atmosphere (pressure range: 2.0-3.0 absolute atmospheres) to treat a disease.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Meet the diagnostic criteria for sudden deafness in the American Academy of Otolaryngology Head and Neck Surgery 2019 Clinical Practice Guidelines for Sudden Deafness; * Aged 18-75 years old; * Patients with unilateral sudden deafness for the first time, and the onset time is less than 2 weeks.

Exclusion criteria

* Patients with other ear diseases, such as auditory trauma, barotrauma, retrocochlear disease, bilateral hearing loss, history of chronic otitis media in the same ear, and history of surgery in the same ear; * Patients with serious primary diseases such as heart, liver, kidney dysfunction and hematopoietic system diseases; * Pregnant and nursing patients; * Accompanied by serious mental illness; * Patients with incomplete clinical data.

Design outcomes

Primary

Measure	Time frame	Description
Hearing recovery rate	From onset to 3 months after treatment	The rate of hearing recovery in patients with all levels of hearing loss at completion of treatment and at 3 months after termination of treatment was assessed according to the WHO Hearing Loss Rating Criteria 2021 to determine the success of treatment.

Countries

China

Contacts

Primary ContactSun Yuting

syt_354@163.com+89 198 2175 8594

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026